Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: J Stone who wrote (26615)	11/18/1998 2:04:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

I find it very sad that the FDA panel would choose to "eyeball" pictures rather then believe the testimony of Dr.'s and patients who worked with the product. One group which worked with the product was an independent organization that duplicated L's results.

To: J Stone who wrote (26615)	11/18/1998 2:08:00 PM
From: Cheryl Galt	Respond to of 32384

Jeff, you say "Basically, I'll be holding my breath..." Looks like the market is too. 9.875, ask 10, vol only 83.8K at 1:45pm est Seems to be holding at around $10 on a comfortable market day As Celery said, "... savvy investors are waiting..." Regards, Cheryl

To: J Stone who wrote (26615)	11/18/1998 2:12:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< The comments gave me the sense that LGND management should have been more careful in what they submitted and perhaps how they submitted it. >> Ligand had delayed the submission of the Panretin Gel KS NDA in order to include additional test results. Right now, that seems like it was a good idea. I too was a little surprised about the debate over what the photos represented. 50% of the photos were questioned. Even so, the panel voted for approval, which means that there were significant results and patient testimony showing the effectiveness of Panretin Gel. I did find it a little disheartening to see the negative emphasis being put on a visual interpretation of non standardized photos. I agree that Ligand seems to have dropped the ball concerning the "quality" of the photo presentation. << I'm not assuming that they won't get approval by year-end. I am worried that they might not. >> I think that most of us are in the same boat. However, the odds are on our side based on the combination of the panel vote for approval, significant clinical test results and an apparently effective "topical" treatment, with acceptable side effects, for a currently non-treatable ailment. Regards, Bob